Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4809-4816

  Wei, Daoyan ^a   Gong, Weida ^a   Oh, Sang C ^a   Li, Qiang ^a   Kim, Won Dong ^a   Wang, Liwei ^a   Le, Xiangdong ^a   Yao, James ^a   Wu, Tsung T ^a   Huang, Suyun ^a   Xie, Keping ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1B; TRANSCRIPTION FACTOR RUNX3;

ADULT; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL CYCLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH MUCOSA; SURVIVAL; TUMOR GROWTH; UPREGULATION;

APOPTOSIS; CASPASES; CELL CYCLE; CELL GROWTH PROCESSES; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CYCLIN D1; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 21144440536     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3741     Document Type: Article

References (43)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
2. Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer 2004;7:61-77.
3. Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell 2004;5:121-5.
4. Tahara E. Molecular aspects of invasion and metastasis of stomach cancer. Verb Dtsch Ges Pathol 2000;84:43-9.
5. Chan AO, Luk JM, Hui WM, Lam SK. Molecular biology of gastric carcinoma: from laboratory to bedside. J Gastroenterol Hepatol 1999;14:1150-60.
6. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat 2003;21:258-70.
7. Sud R, Wells D, Talbot IC, Delhanty JD. Genetic alterations in gastric cancers from British patients. Cancer Genet Cytogenet 2001;126:111-9.
8. Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004;203:681-7.
9. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-4.
10. El-Rifai W, Powell SM. Molecular biology of gastric cancer. Semin Radiat Oncol 2002;12:128-40.
11. Migliavacca M, Ottini L, Bazan V, et al. TP53 in gastric cancer: mutations in the 13 loop and LSH motif DNA-binding domains of TP53 predict poor outcome. J Cell Physiol 2004;200:476-85.
12. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-24.
13. Ito Y. Molecular basis of tissue-specific gene expression mediated by the runt domain transcription factor PEBP2/CBF. Genes Cells 1999;4:685-96.
14. Kania MA, Bonner AS, Duffy JB, Gergen JP. The Drosophila segmentation gene runt encodes a novel nuclear regulatory protein that is also expressed in the developing nervous system. Genes Dev 1990;4:1701-13.
15. Daga A. Karlovich CA, Dumstrei K, Banerjee U. Patterning of cells in the Drosophila eye by Lozenge, which shares homologous domains with AML1. Genes Dev 1996;10:1194-205.
16. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002;2:389-406.
17. Tracey WD. Speck NA. Potential roles for RUNX1 and its ortho-logs in determining hematopoietic cell fate. Semin Cell Dev Biol 2000;11:337-42.
18. Yang S. Wei D. Wang D, et al. In vitro and in vivo synergistic interactions between the Runx2/Cbfa1 transcription factor and bone morphogenetic protein-2 in stimulating osteoblast differentiation. J Bone Miner Res 2003;18:705-15.
19. Westendorf JJ. Hiebert SW. Mammalian runtdomain proteins and their roles in hematopoíesis, osteogenesis, and leukemia. J Cell Biochem 1999; Suppl 32-3:51-8.
20. Ito Y. Oncogenic potential of the RUNX gene family: "overview". Oncogene 2004;23:4198-208.
21. Levanon D, Brenner O, Otto F, Groner Y. Runx3 knockouts and stomach cancer. EMBO Rep 2003;4: 560-4.
22. Levanon D, Bettoun D, Harris-Cerruti C. et al. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J 2002;21:3454-3.
23. Stewart M, MacKay N, Cameron ER, Neil JC. The common retroviral insertion locus Dsi1 maps 30 kilobases upstream of the PI promoter of the murine Runx3/Cbfa3/Aml2 gene. J Virol 2002;76:4364-9.
24. Kim R, Trubetskoy A, Suzuki T, et al. Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas. J Virol 2003;77:2056-62.
25. Wang L, Wei D, Huang S, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003;9:6371-80.
26. Wei D, Wang L, He Y, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004;64:2030-8.
27. Xie K, Wang Y, Huang S, et al. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with down-regulation of Bcl-2. Oncogene 1997;15:771-9.
28. Oshimo Y, Oue N, Mitani Y, et al. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 2004;71:137-43.
29. Kim TY, Lee HJ, Hwang KS, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 2004;84:479-4.
30. Oliveira FJ, Ferrao H, Furtado E, Batista H, Conceicao L. Early gastric cancer: Report of 58 cases. Gastric Cancer 1998;1:51-6.
31. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000;88:921-32.
32. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51: 15-36.
33. Miyazono K, Maeda S, Imamura T. Coordinate regulation of cell growth and differentiation by TGF-β superfamily and Runx proteins. Oncogene 2004;23: 4232-7.
34. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemiaassociated factors AML1 and p300 in myeloid cell differentiation. EMBO J 1998;17:2994-3004.
35. Lee KS, Kim HJ, Li QL, et al. Runx2 is a common target of transforming growth factor β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad3 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000;20:8783-92.
36. Zhang YW, Yasui N, Ito K, et al. A RUNX2/ PEBP2α A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A 2000;97: 10549-54.
37. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
38. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
39. Mithani SK, Balch GC, Shiou SR, et al. Smad3 has a critical role in TGF-β-mediated growth inhibition and apoptosis in colonie epithelial cells. J Surg Res 2004;117: 296-305.
40. Yamamura Y, Hua X. Bergelson S, Lodish HF. Critical role of Smads and AP-1 complex in transforming growth factor-β-dependent apoptosis. J Biol Chem 2000;275: 36295-302.
41. Schuster N, Krieglstein K. Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res 2002;307:1-14.
42. Chipuk JE. Bhat M, Hsing AY, Ma J, Danielpour D. Bcl-xL blocks transforming growth factor-β 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem 2001;276: 26614-21.
43. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1: 222-31.